Table 3.
Mutually exclusive antidiabetic treatment regimens among treated patients (N=557)
| Treatment | Overall N=682 |
Black N=254 |
Hispanic N=269 |
White N=159 |
p Value† |
|---|---|---|---|---|---|
| Number of medications | N (%)* | N (%)* | N (%)* | N (%) | |
| 1 | 340 (61) | 131 (59) | 133 (62) | 76 (62) | 0.87 |
| 2 | 176 (32) | 63 (36) | 77 (29) | 36 (29) | 0.52 |
| 3+ | 41 (7) | 10 (5) | 18 (9) | 13 (8) | 0.51 |
| Biguanides only | 174 (31) | 63 (30) | 69 (33) | 42 (30) | 0.86 |
| Insulin only | 120 (23) | 47 (21) | 51 (20) | 22 (25) | 0.81 |
| Insulin and biguanides only | 70 (16) | 23 (14) | 34 (16) | 13 (17) | 0.87 |
| Biguanides and sulfonylureas only | 70 (11) | 25 (12) | 27 (9) | 18 (11) | 0.69 |
| Sulfonylureas only | 35 (6) | 16 (8) | 9 (7) | 10 (5) | 0.70 |
| Insulin and sulfonylureas only | 11(3) | 7 (5) | 1 (0) | 3 (1) | 0.21 |
| Biguanides, sulfonylureas and thiazolidinediones | 10 (2) | 1 (1) | 5 (2) | 4 (3) | 0.26 |
| Biguanides, insulin and sulfonylureas | 15 (2) | 4 (2) | 6 (3) | 5 (2) | 0.82 |
| Other regimens | 52 (7) | 18 (7) | 26 (10) | 8 (6) | 0.57 |
*Weighted column percentages (may not add up to 100% due to rounding).
†χ2 Test.